PAF (血小板活性化因子) の構造に基づく生理活性物質の合成 : -選択的アゴニストの開発を中心として-

概要

論文の詳細を見る
Since the identification of platelet activating factor (PAF) as alkylacetylglycerophosphocholine, a number of constitutional analogues have been prepared by many laboratories including ours. However those simple constitutional modification of PAF could not make any substantial advance toward the discovery of any useful compounds. At least, one of the most important synthetic goals may be the elaboration of a more selective analogue that keeps good antihypertensive activity with lower platelet aggregation. A molecular design was carried out in such a way to lock or localize the conformational isomers of PAF by introducing methyl group in the glycerine moiety. Thus, tartaric acid strategy allowed us to introduce methyl group at C<SUB>1</SUB> or C<SUB>3</SUB> diastereoselectively and enantioselectively to afford all isomers. Among them, 1 S -Me-PAF has been shown to be the first selective agonist, possessing much stronger antihypertensive activity than PAF itself by oral dose, and rather low platelet activation. The results will be discussed.
社団法人有機合成化学協会の論文